Article

Opko Health Inc. acquires rights for dry eye treatment

Miami-Exclusive rights were acquired by Opko Health Inc. to develop a topical formulation of civamide for ophthalmic use, such as the treatment of dry eye.

Miami-Exclusive rights were acquired by Opko Health Inc. to develop a topical formulation of civamide for ophthalmic use, such as the treatment of dry eye.

Increased tear production was found in more than 50% of treated patients and there were no systematic side effects.

Currently there is only one prescription product approved by FDA for the treatment of dry eye disease.

No terms of the agreement or the company that sold the rights were stated. An intranasal formulation of civamide channel blocker, is being reviewed in phase III trials as a possible treatment for pain.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.